(Q37012062)

17 August 2017

1 reference

title

The immunological challenges of malaria vaccine development (English)

1 reference

17 August 2017

0 references

1 reference

2

Eleanor M Riley

1 reference

17 August 2017

1

Jiraprapa Wipasa

1 reference

PubMed ID

18034650

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

Expert Opinion on Biological Therapy

17 August 2017

1 reference

17 August 2017

7

1 reference

17 August 2017

12

1 reference

17 August 2017

1841-1852

1 reference

Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Glycosylphosphatidylinositol anchors of Plasmodium falciparum: molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

The pathogenic basis of malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Current issues for anti-malarial drugs to control P. falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Preerythrocytic malaria vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

The naturally acquired immunity in severe malaria and its implication for a PfEMP-1 based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Malaria transmission-blocking vaccines: the bonus of effective malaria control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

The vaccine is dead--long live the vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Immunological processes in malaria pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Immunity to non-cerebral severe malaria is acquired after one or two infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Association of transmission intensity and age with clinical manifestations and case fatality of severe Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Induction of proinflammatory responses in macrophages by the glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors, glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Influence of tumor necrosis factor-alpha on the ability of monocytes and lymphocytes to destroy intraerythrocytic Plasmodium falciparum in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Dendritic cells can initiate protective immune responses against malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Induction of specific immune responses against the Plasmodium vivax liver-stage via in vitro activation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Direct processing and presentation of antigen from malaria sporozoites by professional antigen-presenting cells in the induction of CD8 T-cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Interaction of mouse dendritic cells and malaria-infected erythrocytes: uptake, maturation, and antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Dendritic cells induce immunity and long-lasting protection against blood-stage malaria despite an in vitro parasite-induced maturation defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Malaria-specific transgenic CD4(+) T cells protect immunodeficient mice from lethal infection and demonstrate requirement for a protective threshold of antibody production for parasite clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Low interleukin-12 activity in severe Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Reduced interleukin-12 and transforming growth factor-beta1 in severe childhood malaria: relationship of cytokine balance with disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Increased levels of interleukin-12 in Plasmodium falciparum malaria: correlation with the severity of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Changes in cytokine production associated with acquired immunity to Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Innate immune responses to human malaria: heterogeneous cytokine responses to blood-stage Plasmodium falciparum correlate with parasitological and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Malaria parasite-specific Th1-like T cells simultaneously reduce parasitemia and promote disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Tumor necrosis factor and disease severity in children with falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Cytokine expression in the brain in human cerebral malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Differential Induction of TGF-β Regulates Proinflammatory Cytokine Production and Determines the Outcome of Lethal and NonlethalPlasmodium yoeliiInfections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Cross-talk with myeloid accessory cells regulates human natural killer cell interferon-gamma responses to malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Immune response to pre-erythrocytic stages of malaria parasites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Cellular immune responses to Plasmodium falciparum antigens in children receiving long term anti-malarial chemoprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Children in Burkina Faso who are protected by insecticide-treated materials are able to clear drug-resistant parasites better than unprotected children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Heterologous immunity in the absence of variant-specific antibodies after exposure to subpatent infection with blood-stage malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Rationale for development of a synthetic vaccine against plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Naturally acquired antibodies to sporozoites do not prevent malaria: vaccine development implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Stromal niches, plasma cell differentiation and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Maintenance of serum antibody levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Cutting Edge: Long-Term B Cell Memory in Humans after Smallpox Vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Competence and competition: the challenge of becoming a long-lived plasma cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Does malaria suffer from lack of memory?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.12.1841

10.1517/14712598.7.12.1841

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

18034650